Diuretic drug improves core autism symptoms
Double-blind randomized multicenter trial finds bumetanide ameliorates core symptoms of autism.
A medical drug normally used to relieve fluid retention has been repurposed as a treatment for the core symptoms of autism.
Following on from the promising results of their earlier preliminary trials completed in 2010 and 2013, the same team of French researchers and clinicians have recently tested bumetanide again on a larger group of children.
In the new work, published in March 2017 in Translational Psychiatry, the researchers tracked the effects of bumetanide in children with autism taking three different doses of the drug or a placebo. They found that bumetanide appears to decrease the severity of core autism symptoms in a dose-dependent manner.
For their latest study on the effects of bumetanide in autism the French group, led by researcher Yehezkel Ben-Ari, recruited 88 children aged from 2 to 18 years. One group received a placebo, and the others received either 0.5, 1 or 2 milligrams of bumetanide twice daily for three months. Of the 66 children in the bumetanide group, 23 showed an improvement of more than 6 points on the Childhood Autism Rating Scale (CARS), while only 1 of the 22 children in the placebo group made such progress. While the children taking the highest dose of bumetanide, 2 milligrams twice a day, showed the most improvement, this group also recorded the highest number of side effects, such as dehydration, hypokalemia and loss of appetite. The scientists concluded that the “drug presents a favorable benefit/risk ratio at 1mg twice daily”.
Ben-Ari and his team plan to begin recruiting participants for a large multisite European Phase III trial, which will test bumetanide on a group of 370 children, at the dosage of 1mg twice a day. If the study confirms their earlier findings, the drug could be on the market for autism in Europe by 2021.
“Interestingly, responders were found in all subpopulations, ages and ASD severity… Our results suggest that bumetanide known to specifically act on NKCC1 in central neurons attenuated ASD severity.” (Lemonnier 2017)
GABA excitatory switch is the likely mechanism behind positive effects of bumetanide in autism
Apart from helping fluid retention and lowering blood pressure, bumetanide is also known to modulate the levels and activity of chemical messenger, gamma-aminobutyric acid (GABA), thought to play an important role in the underlying pathophysiology of autism.
While the GABA messenger calms neuronal responses, early in development it has the opposite, excitatory, effect in the brain. It is thought that rather than make this developmental switch from excitatory to inhibitory, GABA remains excitatory in children with autism. Recent discoveries in experimental studies also show that adverse events such as severe seizures can reverse GABA’s function from inhibitory to excitatory even in matured, fully developed brains. Giving bumetanide after a seizure reversed the switch and decreased the frequency of seizures in affected animals in a recent Finish study.
“We show that GABA can be linked to structural changes in the brain. One could imagine maybe something similar might be happening in children with autism,” says Claudio Rivera, lead investigator and research director at the University of Helsinki in Finland.
It is worth noting that up to 40% of individuals with autism develop epilepsy at some point in their lives, and a large majority suffer subclinical seizure activity even in the absence of a clinical seizure disorder.
“It is remarkable that we were able to see improvement both behaviourally and functionally in adolescents and young adults with autism36, suggesting that the window of opportunity to learn to decode emotions is not closed at that point of time.” (Hadjikhani 2018)
Bumetanide treatment normalizes amygdala activation in autism in response to eye contact
Results of a more recent, smaller study on bumetanide in adolescents and adults with autism demonstrated that bumetanide reduced threat response to eye contact in study subjects. The participants taking bumetanide spent more time spontaneously engaging in eye contact.
The researchers observed that bumetanide treatment normalized amygdala activation in response to eye contact, and that it increases the time spontaneously spent in observing of emotional faces. These data complemented two previous studies that showed “increased activation in the social brain of participants with autism for emotional vs. neutral faces after bumetanide treatment, and increase of subcortical face-processing network activation in autism compared to controls, including in the amygdala, when gaze is constrained in the eye region.“
“We highlight that a paradoxical response to GABA-enforcing drugs may offer a rationale for administration of bumetanide in individual cases. … The effects of bumetanide on cognition and EEG seemed to mirror the “nonparadoxical” responses to benzodiazepines in healthy subjects.” (Lemonnier 2017)
Ongoing research into bumetanide for autism
A large European multi-centre Phase III trial is currently taking place in France and several other EU countries, including the UK. Children and adolescents with a diagnosis of autism or suspected diagnosis, aged 2-17 years, can participate. Click here for more details or to apply to take part.
Detailed information on this study can also be found on Clinical Trials official registration page
Hadjikhani N., Åsberg Johnels J., Lassalle A., et al. (2018) Bumetanide for autism: more eye contact, less amygdala activation. Sci Rep. Feb 26;8(1):3602. doi: 10.1038/s41598-018-21958-x.
Lemonnier E., Villeneuve N., Sonie S., et al. (2017) Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. Mar 14;7(3):e1056. doi: 10.1038/tp.2017.10.
Bruining H., Passtoors L., Goriounova N., et al. (2015) Paradoxical Benzodiazepine Response: A Rationale for Bumetanide in Neurodevelopmental Disorders? Pediatrics. Aug;136(2):e539-43. doi: 10.1542/peds.2014-4133.
Kourdougli N., Pellegrino C., Renko J.M., et al. (2017) Depolarizing γ-aminobutyric acid contributes to glutamatergic network rewiring in epilepsy. Ann Neurol. Feb;81(2):251-265. doi: 10.1002/ana.24870.
Marrosu F, Marrosu G, Rachel MG, et al. (1987) Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol. 1987 Jul-Sep;2(3):355-61.
‘From Bench to Biopharma’ International Conference on Translational Research in Autism – Day 1 Recap
Synchrony symposia, organised by The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech, is the first and only international conference on translational research in autism that brings together academia, biotech, pharmaceutical companies and...
The Synapse Centre for NeurodevelopmentThe Synapse Centre, based within the ESNEFT (East Suffolk and North Essex NHS Foundation Trust) is a new research centre based in the East of England looking to translate biomedical research into practical therapies for local...
“We must first recognise ASD as a whole body disorder” Autism, or Autism Spectrum Disorder ASD, is traditionally seen as the result of behavioural and neuropsychiatric dysfunction. However there is a strong evidence that various physical, or biomedical, problems can...
The first Brain Foundation annual symposia, Pleasanton, California 8-10 of Nov 2019, aimed to connect researchers with clinicians, donors & stake holders to help translate research efforts into evidence-based treatments for autism and its co-morbidities. It highlighted the need for multidisciplinary collaboration, detailed diagnostics and personalised treatment…
One of the treatment modalities that has shown the greatest promise for reducing symptoms of autism in recent years is transcranial direct current stimulation (tDCS). The most recent study confirmed and expanded on the findings of previous investigations, which strongly indicate that tDCS could have positive effects on cognition, behaviour and physical health, and improve quality of life and autonomy for a large percentage of individuals with autism.
Several studies published in recent months investigated the effects of cannabis-based products for treating autism. Although the studies were open-label and relatively small in scale, the overall results were overwhelmingly positive, with statistically significant improvements in social communication, language, restrictive/repetitive and challenging behaviours.
A small double-blind, placebo-controlled trial shows dramatic effects of suramin as a treatment for autism. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all who received the active treatments, absent in the placebo arm
Children with Congenital Heart Disease, Tuberous Sclerosis Complex, Duchenne Muscular Dystrophy, Ehlers-Danlos Syndrome, Neurofibromatosis Type 1 suffer high rates of autism. Everolimus, an mTOR inhibitor with strong neuro-inflammation attenuating effects, reduces core autism symptoms in some children with TSC, epilepsy and autism…
Numerous medical conditions are significantly more prevalent in children and adults with autism, including allergy and/or immunologic, musculoskeletal, neurologic, psychiatric and gastrointestinal conditions. Early childhood health problems can be used to spot children at high risk of autism…
Adrenocorticotropic hormone therapy in patients with nighttime subclinical seizure activity improves their stuttering and autism symptoms ACTH therapy improves core symptoms of autism alongside EEG parameters and sublinical seizures. In a retrospective study a total...
Babies who are exposed to perinatal complicatios incl. asphyxia, preeclampsia, and meconium-stained amniotic fluid, are at increased risk of developing autism. The risk is especially high for babies exposed to complications both before and during birth.
Accumulating evidence suggests an association between immune dysfunction and pathogenesis of autism spectrum disorders in a large number of affected individuals. Findings from diverse fields of science and experimental animal studies point to close interconnectedness of the immune and the nervous systems